Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 3,093 Shares of Stock

Key Points

• Insider sale: Nuvalent insider Henry Pelish sold 3,093 shares on April 9 at an average price of $104.48 for $323,156.64, cutting his stake by 4.50% to 65,604 shares valued at roughly $6.85 million.
• Market snapshot: Shares traded around $103.69 with a market cap of $8.15 billion, a 12‑month range of $63.56–$113.01, and 50‑/200‑day moving averages near $101.43 and $100.10.
• Investor and analyst sentiment: Institutional investors own 97.26% of the stock, and analysts are broadly positive (16 Buys, 1 Sell) with a consensus "Moderate Buy" and a $137.25 price target.

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Henry Pelish sold 3,093 shares of the company's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the sale, the insider owned 65,604 shares of the company's stock, valued at $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nuvalent Price Performance

Shares of NASDAQ:NUVL traded up $0.95 during midday trading on Monday, hitting $103.69. The company had a trading volume of 321,753 shares, compared to its average volume of 560,479. The company has a market cap of $8.15 billion, a price-to-earnings ratio of -17.72 and a beta of 1.31. Nuvalent, Inc. has a 12-month low of $63.56 and a 12-month high of $113.01. The company has a fifty day moving average of $101.43 and a two-hundred day moving average of $100.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Candriam S.C.A. boosted its holdings in shares of Nuvalent by 9.4% during the 3rd quarter. Candriam S.C.A. now owns 329,721 shares of the company's stock valued at $28,514,000 after purchasing an additional 28,462 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Nuvalent by 9.4% during the 3rd quarter. Voya Investment Management LLC now owns 134,742 shares of the company's stock valued at $11,652,000 after purchasing an additional 11,523 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Nuvalent during the 3rd quarter valued at about $1,297,000. SG Americas Securities LLC bought a new position in shares of Nuvalent during the 3rd quarter valued at about $1,629,000. Finally, HighVista Strategies LLC boosted its holdings in shares of Nuvalent by 84.9% during the 3rd quarter. HighVista Strategies LLC now owns 93,294 shares of the company's stock valued at $8,068,000 after purchasing an additional 42,834 shares during the last quarter. Institutional investors own 97.26% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on NUVL shares. UBS Group reaffirmed a "buy" rating on shares of Nuvalent in a report on Wednesday, December 17th. Wedbush reaffirmed an "outperform" rating and issued a $125.00 target price on shares of Nuvalent in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nuvalent in a report on Thursday, January 22nd. Wells Fargo & Company started coverage on shares of Nuvalent in a report on Monday, March 30th. They issued an "overweight" rating and a $116.00 target price for the company. Finally, Cantor Fitzgerald upped their target price on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Friday, February 27th. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Nuvalent presently has an average rating of "Moderate Buy" and a consensus price target of $137.25.

Nuvalent Company Profile

Nuvalent, Inc NASDAQ: NUVL is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.